A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of SAGE-217 in the Treatment of Adult Subjects With Major Depressive Disorder
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs Zuranolone (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Acronyms MOUNTAIN
- Sponsors Sage Therapeutics
- 15 Nov 2019 Planned End Date changed from 1 Nov 2019 to 1 Apr 2020.
- 12 Nov 2019 According to a SAGE Therapeutics media release, top-line data from the trial is expected in Q4 2019.
- 02 Oct 2019 Status changed from recruiting to active, no longer recruiting, according to a SAGE Therapeutics media release.